Effects of obesity on the cardiovascular system

Handbook of Obesity: Etiology and Pathophysiology, Second Edition

Volumn , Issue , 2003, Pages 825-843

  Saltzman, Edward ^a   Benotti, Peter N ^b  

^a TUFTS UNIVERSITY   (United States)

^b VALLEY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845502187     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (238)

1. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas: AHA, 2000:1–32.
2. Ravussin E. Energy expenditure and body weight. In: Brownell K, Fairburn C, eds. Eating Disorders and Obesity. New York: Guilford Press, 1995:32–37.
3. Frayn KN. Studies of human adipose tissue in vivo. In: Kinney JM, Tucker HN, eds. Energy Metabolism: Tissue Determinants and Cellular Corollaries. New York: Raven Press, 1992:267–291.
4. Messerli FH, Ventura HO, Reisin E, Dreslinski GR, Dunn FG, MacPhee AA, Frohlich ED. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 1982; 66:5560.
5. De Divitiis O, Fazio S, Petitto M, Maddalena G, Contaldo F, Mancini M. Obesity and cardiac function. Circulation 1981; 64:477–482.
6. Licata G, Scaglione R, Barbagallo M, Parrinello G, Capuana G, Lipari R, Merlino G, Ganguzza A. Effect of obesity on left ventricular function studied by radionuclide angiocardiography. Int J Obes 1991; 15:295–302.
7. Messerli FH, Sundgaard-Riise K, Reisin E, Dreslinski G, Dunn FG, Frohlich E. Disparate cardiovascular effects of obesity and arterial hypertension. Am J Med 1983; 74:808–812.
8. Oren S, Grossman E, Frohlich ED. Arterial and venous compliance in obese and nonobese subjects. Am J Cardiol 1996; 77:665–667.
9. Alexander JK. The cardiomyopathy of obesity. Prog Cardiovasc Dis 1985; 27:325–334.
10. Carabello BA, Gittens L. Cardiac mechanics and function in obese normotensive persons with normal coronary arteries. Am J Cardiol 1987; 59:469–473.
11. Wikstrand J, Petterson P, Bjorntorp P. Body fat distribution and left ventricular morphology and function in obese females. J Hypertens 1993; 11:1259–1266.
12. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321:225–236.
13. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. JAMA 1991; 266:231–236.
14. Rasooly R, Sasson Z, Gupta R. Relation between body fat distribution and left ventricular mass in men without structural heart disease or systemic hypertension. Am J Cardiol 1993; 71:1477–1479.
15. Alpert MA, Lambert CR, Terry BE, Cohen MV, Mukerji V, Massey CV, Hashimi MW, Panayiotou H. Interrelationship of left ventricular mass, systolic function and diastolic filling in normotensive morbidly obese patients. Int J Obes 1995; 19:550–557.
16. Gottdiener JS, Reda DJ, Materson BJ, Massie BM, Notargiacomo A, Hamburger RJ, Williams DW, Henderson WG. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol 1994; 24:1492–1498.
17. De Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension 1994; 23:600–606.
18. Bella JN, Devereux RB, Roman MJ, O'Grady MJ, Welty TK, Lee ET, Fabsitz RR, Howard BV. Relations of left ventricular mass to fat-free and adipose body mass: the strong heart study. The Strong Heart Study Investigators. Circulation 1998; 98:2538–2544.
19. Urbina EM, Gidding SS, Bao W, Elkasabany A, Berenson GS. Association of fasting blood sugar level, insulin level, and obesity with left ventricular mass in healthy children and adolescents: the Bogalusa Heart Study. Am Heart J 1999; 138:122–127.
20. Sasson Z, Rasooly Y, Bhensania T, Rasooly I. Insulin resistance is an important determinant of left ventricularmass in the obese. Circulation 1993; 88:1431–1436.
21. Alpert MA, Terry BE, Kelly DL. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. Am J Cardiol 1985; 55:783–786.
22. Noda A, Okada T, Yasuma F, Nakashima N, Yokota M. Cardiac hypertrophy in obstructive sleep apnea syndrome. Chest 1995; 107:1538–1544.
23. Lavie CJ, Messerli FH. Cardiovascular adaptation to obesity and hypertension. Chest 1986; 90:275–279.
24. De la Maza M, Estevez A, Bunout D, Klenner C, Oyonarte M, Hirsch S. Ventricular mass in hypertensive and normotensive obese subjects. Int J Obes 1994; 18:193–197.
25. Lavie CJ, Amodeo C, Ventura HO, Messerli FH. Left atrial abnormalities indicating diastolic ventricular dysfunction in cardiopathy of obesity. Chest 1987; 92:1042–1046.
26. Smith HL, Willius FA. Adiposity of the heart: a clinical and pathologic study of one hundred and thirty-six obese patients. Ann Intern Med 1933; 52:930–931.
27. Carpenter HM. Myocardial fat infiltration. Am Heart J 1962; 63:491–496.
28. Amad KH, Brennan JC, Alexander JK. The cardiac pathology of chronic exogenous obesity. Circulation 1965; 32:740–745.
29. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345–352.
30. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. Ann Intern Med 1989; 110:101–107.
31. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273:1592–1597.
32. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992; 117:831–836.
33. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173–178.
34. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999; 131:376–386.
35. Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, Wong ND, Smith VE, Gottdiener J. M-mode echocardiographic predictors of six to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 2001; 87:1051–1057.
36. Chakko S, Mayor M, Allison MD, Kessler KM, Materson BJ, Myerburg RJ. Abnormal left ventricular diastolic filling in eccentric left ventricular hypertrophy of obesity. Am J Cardiol 1991; 68:95–98.
37. Ku CS, Lin SL, Wang DJ, Chang SK, Lee WJ. Left ventricular filling in young normotensive obese adults. Am J Cardiol 1994; 73:613–615.
38. Crisostomo LL, Araujo LM, Camara E, Carvalho C, Silva FA, Vieira M, Rabelo A Jr. Comparison of left ventricular mass and function in obese versus nonobese women <40 years of age. Am J Cardiol 1999; 84:1127–1129, A1111.
39. Garavaglia GE, Messerli FH, Nunez BD, Schmieder RE, Grossman E. Myocardial contractility and left ventricular function in obese patients with essential hypertension. Am J Cardiol 1988; 62:594–597.
40. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968–977.
41. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow up study. Arch Intern Med 2001; 161:996–1002.
42. Alpert MA, Terry BE, Mulekar M, Cohen MV, Massey CV, Fan TM, Panayiotou H, Mukerji V. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol 1997; 80:736–740.
43. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from ‘diastolic heart failure' or from misdiagnosis? A prospective descriptive study. BMJ 2000; 321:215–218.
44. Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol 1992; 70:921–924.
45. Reisin E, Frohlich ED, Messerli FH, Dreslinski GR, Dunn FG, Jones MM, Batson HM Jr. Cardiovascular changes after weight reduction in obesity hypertension. Ann Intern Med 1983; 98: 315–319.
46. Beretta-Piccoli C. Blood volume changes after weight reduction. Ann Intern Med 1983; 99:568–569.
47. Alpert MA. Management of obesity cardiomyopathy. Am J Med Sci 2001; 321:237–241.
48. Stevens VJ, Corrigan SA, Obarzenek E. Weight loss intervention in phase 1 of the trials of hypertension prevention. Arch Intern Med 1993; 153:849–858.
49. Blumenthal JA, Sherwood A, Gullette EC, Babyak M, Waugh R, Georgiades A, Craighead LW, Tweedy D, Feinglos M, Appelbaum M, Hayano J, Hinderliter A. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med 2000; 160:1947–1958.
50. Minami J, Kawano Y, Ishimitsu T, Matsuoka H, Takishita S. Acute and chronic effects of a hypocaloric diet on 24-hour blood pressure, heart rate and heart rate variability in mildly-to-moderately obese patients with essential hypertension. Clin Exp Hypertens 1999; 21:1413–1427.
51. Benotti PN, Bistrian B, Benotti JR, Blackburn G, Forse RA. Heart disease and hypertension in severe obesity: the benefits of weight reduction. Am J Clin Nutr 1992; 55:586S-590S.
52. Foley E, Benotti P, Borlase B, et al. Impact of gastric restrictive surgery on hypertension in the morbidly obese. Am J Surg 1992; 186:294–297.
53. Carson JL, Ruddy ME, Duff AE, et al. The effect of gastric bypass surgery on hypertension in morbidly obese patients. Arch Intern Med 1994; 154:193–200.
54. Wirth A, Kroger H. Improvement of left ventricular morphology and function in obese subjects following a diet and exercise program. Int J Obes 1995; 19: 61–66.
55. Jordan J, Messerli F, Lavie C, Aepfelbacher F, Soria F. Reduction of weight and left ventricular mass with serotonin uptake inhibition in obese patients with systemic hypertension. Am J Cardiol 1995; 75:743–744.
56. Himeno E, Nishino K, Nakashima Y, Kuroiwa A, Ikeda M. Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. Am Heart J 1996; 131: 313–319.
57. MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 1986; 314:334–339.
58. Sido Z, Jako P, Pavlik G. The effect of moderate weight loss on echocardiographic parameters in obese female patients. Acta Physiol Hung 2000; 87:241–251.
59. Reid CM, Dart AM, Dewar EM, Jennings GL. Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects. J Hypertens 1994; 12: 291–301.
60. DasGupta P, Ramhanmdany E, Brigden G, Lahiri A, Baird IM, Raftery EB. Improvement in left ventricular function after rapid weight loss in obesity. Eur Heart J 1992; 13: 1060–1066.
61. Karason K, Wallentin I, Larsson B, Sjostrom L. Effects of obesity and weight loss on cardiac function and valvular performance. Obes Res 1998; 6:422–429.
62. Alpert MA, Lambert CR, Terry BE, Kelly DL, Panayiotou H, Mukerji V, Massey CV, Cohen MV. Effect of weight loss on left ventricular mass in nonhypertensive morbidly obese patients. Am J Cardiol 1994; 73:918–921.
63. Alpert MA, Terry BE, Lambert CR, Kelly DL, Panayiotou H, Mukerji V, Massey CV, Cohen MV. Factors influencing left ventricular systolic function in nonhypertensive morbidly obese patients, and effect of weight loss induced by gastroplasty. Am J Cardiol 1993; 71:733–737.
64. Alpert MA, Lambert CR, Terry BE, Cohen MV, Mulekar M, Massey CV, Hashimi MW, Panayiotou H, Mukerji V. Effect of weight loss on left ventricular diastolic filling in morbid obesity. Am J Cardiol 1995; 76:1198–1201.
65. Alpert MA, Lambert CR, Panayiotou H, Terry BE, Cohen MV, Massey CV, Hashimi MW, Mukerji V. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995; 76:1194–1197.
66. Frank S, Colliver JA, Frank A. The electrocardiogramin obesity: statistical analysis of 1, 029 patients. J Am Coll Cardiol 1986; 7:295–299.
67. Alpert MA, Terry BE, Cohen MV, Fan TM, Painter JA, Massey CV. The electrocardiogram in morbid obesity. Am J Cardiol 2000; 85:908–910, A910.
68. Alpert MA, Terry BE, Hamm CR, Fan TM, Cohen MV, Massey CV, Painter JA. Effect of weight loss on the ECG of normotensive morbidly obese patients. Chest 2001; 119:507–510.
69. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of left ventricular hypertrophy: test performance in relation to definition of hypertrophy and presence of obesity. J Am Coll Cardiol 1996; 27:124–131.
70. Okin PM, Roman MJ, Devereux RB, Kligfield P. ECG identification of left ventricular hypertrophy. Relationship of test performance to body habitus. J Electro cardiol 1996; 29:256–261.
71. el-Gamal A, Gallagher D, Nawras A, Gandhi P, Gomez J, Allison DB, Steinberg JS, Shumacher D, Blank R, Heymsfield SB. Effects of obesity on QT, RR, and QTC intervals. Am J Cardiol 1995; 75:956–959.
72. Mshui ME, Saikawa T, Ito K, Hara M, Sakata T. QT interval and QT dispersion before and after diet therapy in patients with simple obesity. Exp Biol Med 1999; 220:133–138.
73. Carella MJ, Mantz SL, Rovner DR, Willis PW III, Gossain VV, Bouknight RR, Ferenchick GS. Obesity, adiposity, and lengthening of the QT interval: improvement after weight loss. Int J Obes 1996; 20:938–942.
74. Nagy D, DeMeersman R, Gallagher D, Pietrobelli A, Zion AS, Daly D, Heymsfield SB. QTC interval (cardiac repolarization): lengthening after meals. Obes Res 1997; 5:531–537.
75. Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death: increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987; 147:1725–1728.
76. Karason K, Molgaard H, Wikstrand J, Sjostrom L. Heart rate variability in obesity and the effect of weight loss. Am J Cardiol 1999; 83:1242–1247.
77. Zemva A, Zemva Z. Ventricular ectopic activity, left ventricular mass, hyperinsulinemia, and intracellular magnesium in normotensive patients with obesity. Angiology 2000; 51:101–106.
78. Messerli F, Soria F. Ventricular dysrhythmias, left ventricular hypertrophy, and sudden death. Cardiovasc Drugs Ther 1994; 8:557–563.
79. Bharati S, Lev M. Cardiac conduction system involvement in sudden death of obese young people. Am Heart J 1995; 129:273–281.
80. Van Ravenswaaij-Arts CMA, Kollee LAA, Hopman JCW, Stoelinga GBA, Van Geijn HP. Heart rate variability. Ann Intern Med 1993; 118:436–447.
81. Colhoun HM, Francis DP, Rubens MB, Underwood SR, Fuller JH. The association of heart-rate variability with cardiovascular risk factors and coronary artery calcification: a study in type 1 diabetic patients and the general population. Diabetes Care 2001; 24:1108–1114.
82. Zahorska-Markiewicz B, Kuagowska E, Kucio C, Klin M. Heart rate variability in obesity. Int J Obes 1993; 17:21–23.
83. Emdin M, Gastaldelli A, Muscelli E, Macerata A, Natali A, Camastra S, Ferrannini E. Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. Circulation 2001; 103:513–519.
84. Rissanen PF-KARA. Cardiac parasympathetic activity is increased by weight loss in healthy obese women. Obes Res 2001;9:637–643.
85. Hirsch J, Leibel RL, Mackintosh R, Aguirre A. Heart rate variability as a measure of autonomic function during weight change in humans. Am J Physiol 1991; 261:R1418-R1423.
86. Koenig SM. Pulmonary complications of obesity. Am J Med Sci 2001; 321:249–279.
87. Koehler U, Becker HF, Grimm W, Heitmann J, Peter JH, Schafer H. Relations among hypoxemia, sleep stage, and bradyarrhythmia during obstructive sleep apnea. Am Heart J 2000; 139:142–148.
88. Valencia-Flores M, Orea A, Castano VA, Resendiz M, Rosales M, Rebollar V, Santiago V, Gallegos J, Campos RM, Gonzalez J, Oseguera J, Garcia-Ramos G, Bliwise DL. Prevalence of sleep apnea and electrocardiographic disturbances in morbidly obese patients. Obes Res 2000; 8:262–269.
89. Chadwick J, Mann WN. The Medical Works of Hippocrates. Oxford: Blackwell Scientific, 1950.
90. Kannel WB, Plehn JF, Cupples LA. Cardiac failure and sudden death in the Framingham Study. Am Heart J 1988; 115:869–875.
91. Drenick EJ, Fisler JS. Sudden cardiac arrest in morbidly obese surgical patients unexplained after autopsy. Am J Surg 1988; 155:720–726.
92. Spooner PM, Albert C, Benjamin EJ, Boineau R, Elston RC, George AL Jr, Jouven X, Kuller LH, MacCluer JW, Marban E, Muller JE, Schwartz PJ, Siscovick DS, Tracy RP, Zareba W, Zipes DP. Sudden cardiac death, genes, and arrhythmogenesis: consideration of new population and mechanistic approaches from a National Heart, Lung, and Blood Institute workshop, part I. Circulation 2001; 103:2361–2364.
93. Van Itallie TB, Yang MU. Cardiac dysfunction in obese dieters: a potentially lethal complication of rapid, massive weight loss. Am J Clin Nutr 1984; 39:695–702.
94. Brown JM, Yetter JF, Spicer MJ, Jones JD. Cardiac complications of protein-sparing modified fasting. JAMA 1978; 240:120–122.
95. Singh BN, Gaarder TD, Kanegae T, Goldstein M, Montgomerie JZ, Mills H. Liquid protein diets and torsade de pointes. JAMA 1978; 240:115–119.
96. Sours HE, Frattali VP, Brand CD, Feldman RA, Forbes AL, Swanson RC, Paris AL. Sudden death associated with very low calorie weight reduction regimens. Am J Clin Nutr 1981; 34:453–461.
97. Isner JM, Sours HE, Paris AL, Ferrans VJ, Roberts WC. Sudden, unexpected death in avid dieters using the liquid-protein-modified-fast diet. Observations in 17 patients and the role of the prolonged QT interval. Circulation 1979; 60:1401–1412.
98. Fisler JS. Cardiac effects of starvation and semistarvation diets: safety and mechanisms of action. Am J Clin Nutr 1992; 56:230S-234S.
99. Seim HC, Mitchell JE, Pomeroy C, de Zwaan M. Electrocardiographic findings associated with very low calorie dieting. Int J Obes 1995; 19:817–819.
100. Doherty JU, Wadden TA, Zuk L, Letizia KA, Foster GD, Day SC. Long-term evaluation of cardiac function in obese patients treated with a very-low-calorie diet: a controlled clinical study of patients without underlying cardiac disease. Am J Clin Nutr 1991; 53:854–858.
101. Pietrobelli A, Rothacker D, Gallagher D, Heymsfield SB. Electrocardiographic QTC interval: short-term weight loss effects. Int J Obes 1997; 21:110–114.
102. Zuckerman E, Yeshurun D, Goldhammer E, Shiran A. 24 h electrocardiographic monitoring in morbidly obese patients during short-term zero calorie diet. Int J Obes 1993; 17:359–361.
103. Pringle T, Scobie T, Murray R, Kesson C, Maccuish A. Prolongation of the QT interval during therapeutic starvation: a substrate for malignant arrhythmias. Int J Obes 1983; 7:253–261.
104. Weigle DS, Callahan DB, Fellows CL, Greene HL. Preliminary assessment of very low calorie diets by conventional and signal-averaged electrocardiography. Int J Obes 1989; 13:691–697.
105. Moyer CL, Holly RG, Amsterdam EA, Atkinson RL. Effects of cardiac stress during a very-low-calorie diet and exercise program in obese women. Am J Clin Nutr 1989; 50:1324–1327.
106. Linet OI, Butler D, Caswell K, Metzler C, Reele SB. Absence of cardiac arrhythmias during a very-low calorie diet with high biological quality protein. Int J Obes 1983; 7:313–320.
107. Phinney SD, Bistrian BR, Kosinski E, Chan DP, Hoffer LJ, Rolla A, Schachtel B, Blackburn GL. Normal cardiac rhythm during hypocaloric diets of varying carbohydrate content. Arch Intern Med 1983; 143:2258–2261.
108. Lantigua RA, Amatruda JM, Biddle TL, Forbes GB, Lockwood DH. Cardiac arrhythmias associated with a liquid protein diet for the treatment of obesity. N Engl J Med 1980; 303:735–738.
109. Amatruda JM, Biddle TL, Patton ML, Lockwood DH. Vigorous supplementation of a hypocaloric diet prevents cardiac arrhythmias and mineral depletion. Am J Med 1983; 74: 1016–1022.
110. Lowy SL, Fisler JS, Drenick EJ. Zinc and copper nutriture in obese men receiving very low calorie diets of soy or collagen protein. Am J Clin Nutr 1986; 43:272–287.
111. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997; 96: 3248–3250.
112. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001; 134:224–238.
113. Tracy RP. Is visceral adiposity the ‘enemy within'? Arterioscler Thromb Vasc Biol 2001; 21:881–883.
114. Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both? Circulation 1998; 97:2000–2002.
115. Ross R. Mechanisms of disease: atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340:115–126.
116. Festa A, D'Agostino R, Williams K, Karter AJ, Mayer Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes 2001; 25:1407–1415.
117. Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J, Despres JP. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21:961–967.
118. Mendall MA, Patel P, Ballam L, Strachan D, North field TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061–1065.
119. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237–242.
120. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C- reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19:972–978.
121. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17:2167–2176.
122. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481–2485.
123. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47:403–411.
124. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148:209–214.
125. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767–1772.
126. Marckmann P. Dietary treatment of thrombogenic disorders related to the metabolic syndrome. Br J Nutr 2000; 83:S121-S126.
127. De Lorenzo F, Mukherjee M, Kadziola Z, Suleiman S, Kakkar VV. Association of overall adiposity rather than body mass index with lipids and procoagulant factors. Thromb Haemost 1998; 80:603–606.
128. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133:81–91.
129. Vambergue A, Rugeri L, Gaveriaux V, Devos P, Martin A, Fermon C, Fontaine P, Jude B. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Thromb Res 2001; 101:367–375.
130. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, Arveiler D, Juhan-Vague I. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10, 500 male participants in a prospective study of myocardial infarction—the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998; 80:749–756.
131. Benchimol D, Dubroca B, Bernard V, Lavie J, Paviot B, Benchimol H, Couffinhal T, Pillois X, Dartigues J, Bonnet J. Short- and long-term risk factors for sudden death in patients with stable angina. Int J Cardiol 2000; 76:147–156.
132. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993; 22:S1-S14.
133. Tack CJ, Ong MK, Lutterman JA, Smits P. Insulininduced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia 1998; 41:569–576.
134. Watts GF, Herrmann S, Riches FM. Effects of diet and serotonergic agonist on hepatic apolipoprotein B-100 secretion and endothelial function in obese men. Q J Med 2000; 93:153–161.
135. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97:2601–2610.
136. Steinberg HO, Paradisi G, Cronin J, Crowde K, Hempfling A, Hook G, Baron AD. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 2000; 101:2040–2046.
137. Abdu TA, Elhadd T, Pfeifer M, Clayton RN. Endothelial dysfunction in endocrine disease. Trends Endocrinol Metab 2001; 12:257–265.
138. Al Suwaidi J, Higano ST, Holmes DR Jr, Lennon R, Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 2001; 37:1523–1528.
139. Reed D, Yano K. Predictors of arteriographically defined coronary stenosis in the Honolulu Heart Program. Am J Epidemiol 1991; 134:111–122.
140. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995; 141:1117–1127.
141. Adams-Campbell LL, Peniston RL, Kim KS, Mensah E. Body mass index and coronary artery disease in African-Americans. Obes Res 1995; 3:215–219.
142. Fitzgerald A, Jarrett R. Body weight and coronary heart disease mortality: an analysis in relation to age and smoking habit. 15 years follow-up data from the Whitehall Study. Int J Obes Relat Metab Disord 1992; 16(2):119.
143. Kuhn FE, Rackley CE. Coronary artery disease in women. Arch Intern Med 1993; 153:2626–2636.
144. Keys A, Aravanis C, Blackburn H, Van Buchem F, Buzina R, Djordjevic B, Fidanza F, Karvonen M, Menotti A, Puddu V, Taylor H. Coronary heart disease: overweight and obesity as risk factors. Ann Intern Med 1972; 77:15–27.
145. Clark LT, Emerole O. Coronary heart disease in African Americans: primary and secondary prevention. Cleve Clin J Med 1995; 62:285–292.
146. Caralis PV. Coronary heart disease in Hispanic Americans: how does ethnic background affect risk factors and mortality rates? Postgrad Med 1992; 91:179–188.
147. Howard BV, Lee ET, Cowan LD, Fabsitz RR, Howard WJ, Oopik AJ, Robbins DC, Savage PJ, Yeh JL, Welty TK. Coronary heart disease prevalence and its relation to risk factors in American Indians: the Strong Heart Study. Am J Epidemiol 1995; 142:254–268.
148. Robertson TL, Kato H, Rhoads GG. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: incidence of myocardial infarction and death from coronary heart disease. Am J Cardiol 1977; 39:239–243.
149. Wilson PWF. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994; 7:7S-12S.
150. Keil JE, Sutherland SE, Knapp RG, Lackland DT, Gazes PC, Tyroler H. Mortality rates and risk factors for coronary disease in black as compared with white men and women. N Engl J Med 193; 329:73–78.
151. Barrett-Connor E. Obesity, atherosclerosis, and coronary artery disease. Ann Intern Med 1985; 103:1010–1019.
152. Clark L, Karve M, Rones K, Chang-DeMoranville B, Atluri S, Feldman J. Obesity, distribution of body fat and coronary artery disease in black women. Am J Cardiol 1994; 73:895–896.
153. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO. Overall and coronary heart disease mortality rates in relation to major risk factors in 325, 348 men screened for the MRFIT. Am Heart J 1986; 112: 825–836.
154. Harris TB, Ballard-Barbasch R, Madans J, Makuc DM, Feldman JJ. Overweight, weight loss, and risk of coronary heart disease in older women. Am J Epidemiol 1993; 137:1318–1327.
155. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322:882–889.
156. Manson JE, Willett WC, Stampfer MI, Colditz GA, Hunter DI, Hankanson SE, Henneken CE, Speizer FE. Body weight and mortality among women. N Engl J Med 1995; 333:667–685.
157. Conway G, Agrawal R, Betteridge D, Jacobs H. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992; 37:119–125.
158. Folsom AR, Stevens J, Schreiner PJ, McGovern PG. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Atherosclerosis Risk in Communities study investigators. Am J Epidemiol 1998; 148:1187–1194.
159. Morricone L, Ferrari M, Enrini R, Inglese L, Giardini D, Garancini P, Caviezel F. The role of central fat distribution in coronary artery disease in obesity: comparison of nondiabetic obese, diabetic obese, and normal weight subjects. Int J Obes 1999; 23: 1129–1135.
160. Freedman DS, Williamson DF, Croft JB, Ballew C, Byers T. Relation of body fat distribution to ischemic disease: the National Health and Nutrition Examination Survey I (NHANES I) epidemiologic follow-up study. Am J Epidemiol 1995; 142:53–63.
161. Must A, Jaques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term mobidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med 1992; 327:1350–1355.
162. Pearson TA, Derby CA. Invited commentary: should arteriographic case-control studies be used to identify causes of atherosclerotic coronary artery disease?. Am J Epidemiol 1991; 134:123–128.
163. Stern M. Epidemiology of obesity and its link to heart disease. Metabolism 1995; 44: 1–3.
164. Kannel W, D'Agostino R, Cobb J. Effect of weight on cardiovascular disease. Am J Clin Nutr 1996; 63(suppl): 419S-422S.
165. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341:1097–1105.
166. Lapidus L, Bengtsson C, Larson B, Pennert B, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the populations study of women in Gothenburg, Sweden. BMJ 1984; 289: 1257–1260.
167. Terry RB, Page WF, Haskell WL. Waist/hip ratio, body mass index and premature cardiovascular disease mortality in US Army veterans during a twenty-three year follow-up study. Int J Obes 1992; 16: 417–423.
168. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE. Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280: 1843–1848.
169. Folsom AR, Kushi LH, Anderson KE, Mink PJ, Olson JE, Hong CP, Sellers TA, Lazovich D, Prineas RJ. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. Arch Intern Med 2000; 160:2117–2128.
170. Coleman MP, Key TJA, Wang DY, Hermon C, Fentiman IS, Allen DS, Jarvis M, Pike MC, Sanders TAB. A prospective study of obesity, lipids, apolipoproteins and ischaemic disease in women. Atherosclerosis 1992; 92: 177–185.
171. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol 1977; 39:452–458.
172. Kumanyika S. Searching for the association of obesity with coronary artery disease. Obes Res 1995; 3: 273–275.
173. Kumanyika SK. Special issues regarding obesity in minority populations. Ann Intern Med 1993; 119:650–654.
174. Stern M, Patterson J, Mitchell B, Haffner S, Hazuda H. Overweight and mortality in Mexican-Americans. Int J Obes 1990; 14: 623–629.
175. Welty TK, Lee ET, Yeh J, Cowan LD, Go O, Fabsitz RR, Le NA, Oopik AJ, Robbins DC, Howard BV. Cardiovascular disease risk factors among American Indians: the Strong Heart Study. Am J Epidemiol 1995; 142:269–287.
176. Hansen C, Woodhouse S, Kramer M. Effect of patient obesity on the accuracy of thallium-201 myocardial perfusion imaging. Am J Cardiol 2000; 85:749–754.
177. Schwann TA, Habib RH, Zacharias A, Parenteau GL, Riordan CJ, Durham SJ, Engoren M. Effects of body size on operative, intermediate, and long-term outcomes after coronary artery bypass operation. Ann Thorac Surg 2001; 71:521–530.
178. Allen KB, Heimansohn DA, Robison RJ, Schier JJ, Griffith GL, Fitzgerald EB, Isch JH, Abraham S, Shaar CJ. Risk factors for leg wound complications following endoscopic versus traditional saphenous vein harvesting. Heart Surg Forum 2000; 3:325–330.
179. Weiss YG, Merin G, Koganov E, Ribo A, Oppenheim Eden A, Medalion B, Peruanski M, Reider E, Bar-Ziv J, Hanson WC, Pizov R. Postcardiopulmonary bypass hypoxemia: a prospective study on incidence, risk factors, and clinical significance. J Cardiovasc Vasc Anesth 2000; 14:506–513.
180. Yamagishi T, Ishikawa S, Ohtaki A, Takahashi T, Ohki S, Morishita Y. Obesity and postoperative oxygenation after coronary artery bypass grafting. Jpn J Thorac Cardiovasc Surg 2000; 48:632–636.
181. Kurki TS, Kataja M. Preoperative prediction of postoperative morbidity in coronary artery bypass grafting. Ann Thorac Surg 1996; 61: 1740–1745.
182. Sabourin CB, Funk M. Readmission of patients after coronary artery bypass graft surgery. Heart Lung 1999; 28: 243–250.
183. Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, Speizer FE, Manson JE. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277: 1539–1545.
184. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med 1995; 333:1392–1400.
185. Welin L, Svardsudd K, Wilhelmsen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 1987; 317:521–526.
186. Mavri A, Stegnar M, Sentocnik JT, Videcnik V. Impact of weight reduction on early carotid atherosclerosis in obese premenopausal women. Obes Res 2001; 9:511–516.
187. Lakka TA, Lakka HM, Salonen R, Kaplan GA, Salonen JT. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis 2001; 154:497–504.
188. Karason K, Wikstrand J, Sjostrom L, Wendelhag I. Weight loss and progression of early atherosclerosis in the carotid artery: a four-year controlled study of obese subjects. Int J Obes 1999; 23:948–956.
189. Gillum RF. Risk factors for stroke in blacks: a critical review. Am J Epidemiol 1999; 150:1266–1274.
190. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke 1998; 29:1860–1866.
191. Du X, McNamee R, Cruickshank K. Stroke risk from multiple risk factors combined with hypertension: a primary care based case-control study in a defined population of northwest England. Ann Epidemiol 2000; 10:380–388.
192. Temelkova-Kurktschiev T, Koehler C, Schaper F, Henkel E, Hahnefeld A, Fuecker K, Siegert G, Hanefeld M. Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals. Diabetologia 1998; 41:706–712.
193. Mainard F, Auget JL, Vest P, Madec Y. Comparative study of risk factors in patients undergoing coronary or femoropopliteal artery bypass grafting. Br Heart J 1994; 72:542–547.
194. Gofin R, Kark JD, Friedlander Y, Lewis BS, Witt H, Stein Y, Gotsman MS. Peripheral vascular disease in a middle-aged population sample. The Jerusalem Lipid Research Clinic Prevalence Study. Isr J Med Sci 1987; 23:157–167.
195. Ness J, Aronow WS, Ahn C. Risk factors for symptomatic peripheral arterial disease in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc 2000; 48:312–314.
196. Giltay EJ, Lambert J, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Arterial compliance and distensibility are modulated by body composition in both men and women but by insulin sensitivity only in women. Diabetologia 1999; 42:214–221.
197. Gariepy J, Salomon J, Denarie N, Laskri F, Megnien JL, Levenson J, Simon A. Sex and topographic differences in associations between large-artery wall thickness and coronary risk profile in a French working cohort: the AXA Study. Arterioscler Thromb Vasc Biol 1998; 18:584–590.
198. Plavnik FL, Ajzen S, Kohlmann O Jr, Tavares A, Zanella MT, Ribeiro AB, Ramos OL. Intima-media thickness evaluation by B-mode ultrasound. Correlation with blood pressure levels and cardiac structures. Brazil J Med Biol Res 2000; 33:55–64.
199. MacMahon SW, Macdonald GJ, Bernstein L, Andrews G, Blacket RB. A randomized controlled trial of weight reduction and metoprolol in the treatment of hypertension in young overweight patients. Clin Exp Pharmacol Physiol 1985; 12:267–271.
200. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, Milas NC, Mattfeldt-Beman M, Belden L, Bragg C, Millstone M, Raczynski J, Brewer A, Singh B, Cohen J. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134:1–11.
201. Kelley D. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 1995; 3:366–377.
202. Letiexhe MR, Scheen AJ, Gerard PL, Desaive C, Lefebvre PJ. Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obes 1994; 18:295–300.
203. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998; 52:329–333.
204. Rissanen P. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes 2001; 25:212–218.
205. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001; 21:968–970.
206. Williamson DF, Pamuk ER. The association between weight loss and increased longevity. A review of the evidence. Ann Intern Med 1993; 119:731–736.
207. French SA, Folsom AR, Jeffery RW, Williamson DF. Prospective study of intentionality of weight loss and mortality in older women: the Iowa Women's Health Study. Am J Epidemiol 1999; 149:504–514.
208. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23:1499–1504.
209. Kuller LH. Invited commentary on ‘Prospective study of intentionality of weight loss and mortality in older women: the Iowa Women's Health Study' and ‘Prospective study of intentional weight loss and mortality in overweight white men aged 40–64 years'. Am J Epidemiol 1999; 149:515–516.
210. Connolly HM, Crary JL, McGoon D, Hensrud DD, Edwards BS, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:581–588.
211. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:635.
212. Cannistra LB, Davis SM, Bauman AG. Valvular heart disease associated with dexfenfluramine. N Engl J Med 1997; 337:636.
213. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR 1997; 46: 1061–1066.
214. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998; 339:725–732.
215. Davidoff R, McTiernan A, Constantine G, Davis KD, Balady GJ, Mendes LA, Rudolph RE, Bowen DJ. Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001; 161:1429–1436.
216. Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, Douglas PS. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998; 129:870–874.
217. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000; 283:1703–1709.
218. Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999; 100:2161–2167.
219. Burger AJ, Sherman HB, Charlamb MJ, Kim J, Asinas LA, Flickner SR, Blackburn GL. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999; 34:1153–1158.
220. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000; 101:2071–2077.
221. Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol 1999; 84:1335–1338.
222. Ryan DH, Bray GA, Helmcke F, Sander G, Volaufova J, Greenway F, Subramaniam P, Glancy DL. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999; 7:313–322.
223. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339:953–959.
224. Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR, Jensen MD. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999; 74:1191–1197.
225. Lepor NE, Gross SB, Daley WL, Samuels BA, Rizzo MJ, Luko SP, Hickey A, Buchbinder NA, Naqvi TZ. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Am J Cardiol 2000; 86:107–110.
226. Teramae CY, Connolly HM, Grogan M, Miller FA Jr. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000; 75:456–461.
227. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetitesuppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339:719–724.
228. Li R, Serdula MK, Williamson DF, Bowman BA, Graham DJ, Green L. Dose-effect of fenfluramine use on the severity of valvular heart disease among fenphen patients with valvulopathy. Int J Obes 1999; 23:926–928.
229. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998; 339:713–718.
230. Weissman NJ, Panza JA, Tighe JF, Gwynne JT. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134:267–273.
231. Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001; 134:261–266.
232. Raeini-Sarjaz M, Vanstone CA, Papamandjaris AA, Wykes LJ, Jones PJ. Comparison of the effect of dietary fat restriction with that of energy restriction on human lipid metabolism. Am J Clin Nutr 2001; 73:262–267.
233. Bach DS, Rissanen AM, Mendel CM, Shepherd G, Weinstein SP, Kelly F, Seaton TB, Patel B, Pekkarinen TA, Armstrong WF. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 1999; 7: 363–369.
234. Griffen L, Anchors M. The ‘phen-pro' diet drug combination is not associated with valvular heart disease. Arch Intern Med 1998; 158:1278–1279.
235. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343:1826–1832.
236. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343:1833–1838.
237. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286:208–216.
238. Messerli FH. Cardiovascular effects of obesity. Lancet 1982; 1:1165–1168.